Hims & Hers strikes GLP-1 deal with Lilly and its stock rallies
FROM THE WIRE · MARKETWATCH.COM
As part of the agreement, Hims said it won't compound GLP-1 medications like Zepbound in the future.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe GLP-1 agreement with Lilly is a company event that can move the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Under the agreement, Hims said it will no longer compound GLP-1 medications like Zepbound.
- 02The Hims & Hers stock is rallying after the announcement.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets